Restless legs syndrome (RLS) is a neurological disorder characterized by an urge to move the legs usually accompanied by unpleasant leg sensations. RLS also impacts health-related quality of life (QOL) in patients suffering from it. Further, it affects women more than men. Although a voluminous literature of studies is available evaluating the role of benzodiazepines (clonazepam) and antidepressant (nortriptyline) in the treatment of RLS, but to the best of our knowledge, no comparative study is available comparing both of these drugs for efficacy and safety for the treatment of RLS QoL among 40 + years old women.

Materials and Methods: A prospective, randomized, open label comparative study was conducted in Postgraduate Department of Pharmacology in collaboration with the Department of General Medicine, Government Medical College, Jammu, a tertiary care teaching hospital for 1 year. Conclusion: Clonazepam proved to be significantly better in improving RLSQoL score. Difference between respective baselines of both groups was statistically insignificant.

Keywords: Clonazepam, Nortriptiline, Plus forty women, Quality of Life, Restless Leg Syndrome
been well established as adjuvant therapy for the control of pain in various disorders such as fibromyalgia, neuropathic pain, LBA, headache, and rheumatological disorders.[11]

The dopamine agonists (levodopa, ropinirole, and pramipexole) are considered as the first line therapy for the treatment of moderate-to-severe RLS. Other treatment options available for RLS as per different studies are iron supplementation, opioids (tramadol and methadone), antiepileptic agents (gabapentin, carbamazepine, lamotrigine, valproate, and pregabalin), antidepressants, and benzodiazepines.[12,13]

Although a voluminous literature of studies is available evaluating the role of benzodiazepines (clonazepam)[14,15] and antidepressant (nortriptyline)[16–18] in the treatment of RLS, but to the best of our knowledge, no comparative study is available comparing both of these drugs for efficacy and safety for the treatment of RLS QoL among 40 + years old women.

Hence, the current prospective, randomized, open label study comparing the efficacy and safety of clonazepam versus nortriptyline in RLS QOL in 40 + years old women was undertaken for 1 year. We hope that the outcome of the proposed study will be of immense value for the treating clinician in instituting the more effective and safe therapy in RLS.

A prospective, randomized, open-label comparative study was conducted in Postgraduate Department of Pharmacology in collaboration with the Department of General Medicine, Government Medical College, Jammu, a tertiary care teaching hospital for 1 year. The study protocol was approved by Institutional Ethics Committee. A written informed consent was obtained from the patients fulfilling inclusion, exclusion criteria after explaining nature and purpose of the study. All principles of bioethics were followed.

**Inclusion criteria**

- Women with any menstrual status
- Age more than 40 years and < 65 years.
- Legitimate consent
- Any uncomplicated comorbid condition.

**Exclusion criteria**

- Pregnancy
- Lactation
- Anemia
- Complicated comorbid conditions
- Primary psychiatric disorder
- Allergy and intolerance to research drugs
- History of any substance dependence or abuse
- Neurological disorders
- Hypotensive akathisia
- Peripheral vascular disease/vascular claudication
- Chronic pain syndrome (lumbar and cervical)
- Sleep-related disorders
- Patients having arthritis, fibromyalgia, and varicose veins
- Patients who are on clonazepam or nortriptyline for the past 4 weeks or more.

**Treatment arms**

Both the treatment arms were allowed to continue with the prescribed medicine for uncomplicated comorbid conditions.

- Group 1 received Tablet Clonazepam 0.5 mg bedtime orally daily
- Group 2 received Tablet Nortriptyline 25 mg bedtime orally daily.

The dose selected for both the drugs was based on the most common clinically used dose for the respective drugs. This was also based on the dose used by various authors in their studies.[19,20]

The primary endpoints efficacy evaluation was carried out at 0, 4, and 8 weeks. The assessment was carried out by QOL by using Restless Legs Quality of Life Scale (RLSQoL) and were compared.

**Restless legs quality of life scale**

QOL was seen by scale RLSQoL. It is a prevalidated and pretested scale. It assesses the impact of RLS on daily life, emotional well being, social life, and work life.[21]

**Validation of restless legs quality of life**

Abetz et al., 2005[21] in their study tried to validate RLSQoL scale score and it was found that RLSQoL summary scale score (range: 0–100) demonstrated acceptable internal consistency reliability (Cronbach’s alpha = 0.92) and test-retest reliability (intraclass correlation coefficient = 0.84). All items indicated acceptable item-convergent validity. The RLSQoL distinguished between groups with mild, moderate, and severe symptoms (F = 52.22, P < 0.0001). It demonstrated preliminary responsiveness to changes in RLS status over 2 weeks (effect size: improvement, 0.25; deterioration,−0.32), indicating moderate scale changes consistent with the small clinical change over this time.

All patients completed their follow up except one in the Nortryptiline group who was lost to follow up for unknown reasons.

Mean RLSQoL score in clonazepam group was 59.85 ± 17 at 0 week, 63.57 ± 16.06 at 4 weeks, and 66.85 ± 15.32 at 8 weeks and the difference was
statistically significant ($P < 0.001$). In Nortriptyline group the mean score was 59.62 ± 15.22 at 0 week, 63.36 ± 14.56 at 4 weeks, and 67.10 ± 13.95 at 8 weeks and the difference was statistically insignificant at 4 weeks and statistically significant at 8 weeks ($P < 0.01$). Clonazepam proved to be significantly better in improving RLSQoL score. Difference between respective baselines of both groups was statistically insignificant [Table 1 and Figure 1].

Mean percentage change of RLSQoL score was 6.21% at 4 weeks, 11.41% at 8 weeks in clonazepam group, and 6.27% at 4 weeks, and 12.54% at 8 weeks in nortriptyline group. Nortriptyline showed relatively more improvement numerically in comparison to clonazepam group [Table 2 and Figure 2].

**DISCUSSION**

In our study, clonazepam showed statistically better improvement on QOL. Nortriptyline recorded its beneficial effect on mood at 8 wks.

Effect of antidepressants on physical day-to-day activity and overall QOL is generally comparable within and between different classes of antidepressants. However, very limited studies could be cited in the review.

The results of the present study are in agreement with various studies.[18,22,23]

Shi et al., 2004[22] in their double-blind, placebo-controlled randomized trial on patients with bipolar depression concluded that antidepressants alone or in combination with olanzapine improved QOL.

The results of the current study are in agreement with the study of Liu WQ et al., 2014[18] where amitriptyline was compared with nortriptyline in the management of pain due to peripheral neuropathy and recorded improvement in sleep efficacy, mood, anxiety, global physical improvement score, disability and overall QOL score, besides being effective in pain amelioration.

Similarly, it was concluded by Zhang et al., 2016[23] that antidepressants alone or in combination can effectively improve social function, QOL and health of an individual with mild depression whereas combined therapy is better than monotherapy, although our study population was nondepressive.

However, we failed to cite studies purely on nortriptyline having an effect on QOL, but we assume that the effect recorded in the current study may be due to direct or indirect improvement in sleep, mood and day-to-day activity in patients of RLS.

The results of the current study also become clinically relevant because RLS has an impact on health-related

![Figure 1: Comparative Effect of Clonazepam versus nortriptyline on Mean Restless Leg Syndrome Quality of Life Score](image1.png)

![Figure 2: Mean Difference (% change) observed with clonazepam versus nortriptyline on Mean Restless Leg Syndrome Quality of Life Score](image2.png)

Table 1: Comparative effect of clonazepam versus nortriptyline on mean Restless Leg Syndrome Quality of Life Score

| Duration | Clonazepam Mean±SD | Nortriptyline Mean±SD | t | P | Statistical significance |
|----------|--------------------|-----------------------|---|---|-------------------------|
| Baseline | 59.85±17.0 (n=60)  | 59.62±15.22 (n=60)    | 0.07 | 0.937 | NS                      |
| 4 weeks  | 63.57±16.06*       | 63.36±14.56 (n=59)    | 1.40 | 0.162 | NS                      |
| 8 weeks  | 66.68±15.32*       | 67.10±13.95* (n=59)   | 0.15 | 0.876 | NS                      |

The data is shown as mean±SD. Paired $t$ test in comparison to respective baselines $^*P<0.05$, $^{**}P<0.01$, $^{***}P<0.001$, $^{****}P<0.001$. Comparison between the groups at baseline, 4 weeks and 8 weeks with student unpaired $t$ test $^*P<0.05$, $P<0.01$, $P<0.001$. NS: Not significant, SD: Standard deviation.
Table 2: Mean difference (percentage change) observed with clonazepam versus nortriptyline on mean Restless Leg Syndrome Quality of Life Score

| Duration | Clonazepam (n=60) (%) | Nortriptyline (n=59) (%) |
|----------|----------------------|--------------------------|
| 4 weeks  | 3.72±0.94 (6.21)      | 3.74±0.66 (6.27)         |
| 8 weeks  | 6.83±1.68 (11.41)     | 7.48±1.25 (12.54)        |

SD: Standard deviation

QOL in the affected patients. It affects women more than men.[1-3]

Further, it is assumed that if longer duration study is done in future nortriptyline may show a better profile on overall QOL contrary to the finding recorded in the current study.

In our study, clonazepam and nortriptyline have shown comparable results on QOL with clonazepam showing statistically better improvement on QoL starting at 4 weeks. This may be directly or indirectly by improving sleep, mood, or day-to-day activity in patients of RLS.

The effect on day-to-day activity by nortriptyline and clonazepam came out to be statistically comparable in our study with nortriptyline showing numerically better effect.

The symptoms of RLS are less noticeable during the daytime, but more prevalent at night. Therefore, the disorder can induce low QOL, insomnia, and impairment of daytime activity. The recommended treatment guidelines for the general population established by Medical Advisory Board of the RLS foundation include dopamine agonists, levodopa, gabapentin, benzodiazepines, and opioid. Thus, improvement on QOL and day-to-day activity by clonazepam may be indirectly by improvement in sleep, mood, and RLS symptoms.

Giddiness (44.4%) was the most common ADR in clonazepam group followed by increased sleep (33.3%), constipation (11.1%), and gastritis (11.1%) whereas in nortriptyline group increased sleep and palpitations (33.3%) were followed by giddiness (25%) and gastritis (8.3%).

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Happe S, Reese JP, Stiasny-Kolster K, Peglau I, Mayer G, Klotsche J, et al. Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med 2009;10:295-305.
2. Wessström J, Nilsson S, Sundström-Poromaa I, Ulfberg J. Health-related quality of life and restless legs syndrome among women in Sweden. Psychiatry Clin Neurosci 2010;64:574-9.
3. Cirillo DJ, Wallace RB. Restless legs syndrome and functional limitations among American elders in the health and retirement study. BMC Geriatr 2012;12:39.
4. Phillips B, Hening W, Britz P, Mannino D. Prevalence and correlates of restless legs syndrome: Results from the 2005 National Sleep Foundation Poll. Chest 2006;129:76-80.
5. Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-92.
6. Allen RP, Bharma M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: Results of a general population survey in the United States. Mov Disord 2011;26:114-20.
7. Cuellar NG, Strumpf NE, Ratcliffie SJ. Symptoms of restless legs syndrome in older adults: Outcomes on sleep quality, sleepiness, fatigue, depression, and quality of life. J Am Geriatr Soc 2007;55:1387-92.
8. Sevim S, Dogu O, Kalegasi H, Aral M, Metin O, Camdeviren H. Correlation of anxiety and depression symptoms in patients with restless legs syndrome: A population based survey. J Neurol Neurosurg Psychiatry 2004;75:226-30.
9. Agüera-Ortiz L, Perez MI, Osorio RS, Sacks H, Palomo T. Prevalence and clinical correlates of restless legs syndrome among psychogeriatric patients. Int J Geriatr Psychiatry 2011;26:1252-9.
10. Comella CL. Treatment of restless legs syndrome. Neurotherapeutics 2014;11:177-87.
11. Mercier A, Auger-Aubin I, Lebeau JP, Schuers M, Boulet P, Hermil JL, et al. Evidence of prescription of antidepressants for non-psychiatric conditions in primary care: An analysis of guidelines and systematic reviews. BMC Fam Pract 2013;14:55.
12. Facheris MF, Hicks AA, Pramstaller PP, Pichler I. Update on the management of restless legs syndrome: Existing and emerging treatment options. Nat Sci Sleep 2010;2:199-212.
13. Buchfuhrer MJ. Strategies for the treatment of restless legs syndrome. Neurotherapeutics 2012;9:776-90.
14. Peled R, Lavie P. Double-blind evaluation of clonazepam on periodic leg movements in sleep. J Neurol Neurosurg Psychiatry 1987;50:1679-81.
15. Shinno H, Oka Y, Otsuki M, Tsuchiya S, Mizuno S, Kawada S, et al. Proposed dose equivalence between clonazepam and pramipexole in patients with restless legs syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:522-6.
16. Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial. Neurology 1998;51:1166-71.
17. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: A double-blind, randomised controlled crossover trial. Lancet 2009;374:1252-61.
18. Liu WQ, Kanungo A, Toth C. Equivalency of tricyclic antidepressants in open-label neuropathic pain study. Acta Neurol Scand 2014;129:132-41.
19. Horiguchi J, Inami Y, Sasaki A, Nishimatsu O, Sukegawa T. Periodic leg movements in sleep with restless legs syndrome: Effect of clonazepam treatment. Jpn J Psychiatry Neurol 1992;46:727-32.
20. Khoromi S, Cui L, Nackers L, Max MB. Morphone, nortriptyline and their combination vs. placebo in patients with chronic...
lumbar root pain. Pain 2007;130:66-75.
21. Abetz L, Vallow SM, Kirsch J, Allen RP, Washburn T, Earley CJ, et al. Validation of the restless legs syndrome quality of life questionnaire. Value Health 2005;8:157-67.
22. Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: Secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther 2004;26:125-34.
23. Zhang B, Ding X, Lu W, Zhao J, Lv Q, Yi Z, et al. Effect of group cognitive-behavioral therapy on the quality of life and social functioning of patients with mild depression. Shanghai Arch Psychiatry 2016;28:18-27.